Reccurent/Metastatic Solid Tumor Disease
2
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
14 treatments under study, led by Targeted Therapy Based On Molecular Profiling Vemurafenib
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
Research Network
Common Treatments
- Targeted Therapy Based On Molecular Profiling Vemurafenib1
- Tumor Biopsy1
- Targeted Therapy Based On Molecular Profiling Erlotinib1
- Standard Chemotherapy1
- Targeted Therapy Based On Molecular Profiling Dasatinib1
Active Sponsors
- TerSera Therapeutics LLC1
- CHU de Quebec-Universite Laval1
- Institut Curie1
Top Investigators
CHU de Québec-Université Laval
Institut Curie
Related Conditions
- Prostatic Neoplasms1
- Neoplasm Recurrence Local1
- Prostate Cancer1
- Prostate Cancer Post Prostatectomy1
- Biochemical Recurrence Of Malignant Neoplasm Of Prostate1